Climb Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-04.
Climb Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 4, 2026. The filing reports $110.08M sold. Its industry group is Biotechnology. It names Aoife Brennan (Executive Officer, Director), Susan Altschuller (Executive Officer), Perrin Wilson (Executive Officer) (SEC Form D, May 4, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Climb Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-05-04 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Climb Bio, Inc.
Free to see. No signup.
More on the people and the money behind Climb Bio, Inc., from the filings we hold.
H.C. Wainwright & Co., LLC received sales compensation on this raise and on 30 other raises we hold, nearest in date first:
Piper Sandler and Co. received sales compensation on this raise and on 19 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Massachusetts, filed in May 2026, largest first.
Get an email when Climb Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Climb Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Climb Bio, Inc. →Get the full cited report on Climb Bio, Inc.
What the filing shows about Climb Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Climb Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Climb Bio, Inc.'s address as 20 William Street, Suite 145, Wellesley Hills, MA 02481.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Climb Bio, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Climb Bio, Inc. is a registered filer with the SEC (CIK 1768446) and has filed since 2024-07-02. 3 filings are on record, the latest on 2026-05-04.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Climb Bio, Inc.'s Form D of 2026-05-04 names Aoife Brennan, Susan Altschuller, Perrin Wilson and 6 more as its officers, directors or promoters.
Its new offerings report $271.95M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week. The dot is this raise, $110.08M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
The Investor Relations website contains information about Climb Bio's business for stockholders, potential investors, and financial analysts.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Aoife Brennan is named as Executive Officer and Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Susan Altschuller is named as Executive Officer on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Perrin Wilson is named as Executive Officer on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Judith Dunn is named as Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Stephen Thomas is named as Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Douglas Williams is named as Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Alexander (Bo) Combo is named as Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Andrew Levin is named as Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
Kimberlee Drapkin is named as Director on the Form D that Climb Bio, Inc. filed with the SEC on 4 May 2026, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2026-05-04 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Climb Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Climb Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Climb Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Climb Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Climb Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (ir.climbbio.com).
Each opens in a new tab, filled in for Climb Bio, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/climb-bio-inc-form-d-26000001